SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 124 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.54 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,252,880 | -4.5% | 155,157 | +37.7% | 0.00% | -100.0% |
| Q2 2023 | $2,359,146 | +3.1% | 112,716 | +4.1% | 0.00% | 0.0% |
| Q1 2023 | $2,287,613 | -48.0% | 108,315 | -37.3% | 0.00% | -50.0% |
| Q4 2022 | $4,397,378 | -35.9% | 172,785 | -39.5% | 0.00% | -33.3% |
| Q3 2022 | $6,861,000 | +12.6% | 285,532 | -9.8% | 0.00% | 0.0% |
| Q2 2022 | $6,092,000 | +62.9% | 316,675 | +47.2% | 0.00% | +200.0% |
| Q1 2022 | $3,740,000 | +21.6% | 215,164 | +53.1% | 0.00% | 0.0% |
| Q4 2021 | $3,076,000 | +128.4% | 140,517 | +99.3% | 0.00% | – |
| Q3 2021 | $1,347,000 | +327.6% | 70,513 | +283.8% | 0.00% | – |
| Q2 2021 | $315,000 | -77.8% | 18,372 | -71.0% | 0.00% | – |
| Q1 2021 | $1,417,000 | +445.0% | 63,372 | +443.3% | 0.00% | – |
| Q4 2020 | $260,000 | +1633.3% | 11,664 | +1066.4% | 0.00% | – |
| Q3 2020 | $15,000 | -96.6% | 1,000 | -96.7% | 0.00% | – |
| Q2 2020 | $446,000 | +156.3% | 30,063 | +89.3% | 0.00% | – |
| Q1 2020 | $174,000 | -35.8% | 15,877 | -48.4% | 0.00% | – |
| Q4 2019 | $271,000 | +66.3% | 30,795 | +41.2% | 0.00% | – |
| Q3 2019 | $163,000 | +207.5% | 21,805 | +284.6% | 0.00% | – |
| Q2 2019 | $53,000 | +381.8% | 5,669 | +183.4% | 0.00% | – |
| Q1 2019 | $11,000 | -76.6% | 2,000 | -80.9% | 0.00% | – |
| Q4 2018 | $47,000 | +88.0% | 10,469 | +232.8% | 0.00% | – |
| Q3 2018 | $25,000 | +78.6% | 3,146 | +57.3% | 0.00% | – |
| Q2 2018 | $14,000 | -70.8% | 2,000 | -40.7% | 0.00% | – |
| Q1 2018 | $48,000 | +166.7% | 3,371 | +68.6% | 0.00% | – |
| Q4 2017 | $18,000 | -33.3% | 2,000 | -15.3% | 0.00% | – |
| Q3 2017 | $27,000 | +237.5% | 2,362 | +336.6% | 0.00% | – |
| Q2 2017 | $8,000 | -60.0% | 541 | -63.3% | 0.00% | – |
| Q1 2017 | $20,000 | +233.3% | 1,473 | +82.3% | 0.00% | – |
| Q4 2016 | $6,000 | -95.6% | 808 | -91.0% | 0.00% | – |
| Q3 2016 | $136,000 | +1411.1% | 8,997 | +933.0% | 0.00% | – |
| Q2 2016 | $9,000 | – | 871 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |